RespireRx Pharmaceuticals (RSPID) Stock Price, News & Analysis

Company Overview

RespireRx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on developing therapies for disorders involving the central nervous system and respiratory function. The company’s research has centered on compounds designed to improve breathing and address neurological conditions.

RespireRx’s development portfolio has included ampakine compounds, including CX1739, an investigational therapy studied for sleep-related breathing disorders such as obstructive sleep apnea. The company has also evaluated other central nervous system drug candidates for potential applications involving attention, cognition, and respiratory depression.

The company was formerly known as Cortex Pharmaceuticals Inc. and adopted the RespireRx Pharmaceuticals name as its strategic focus shifted toward respiratory and neurological indications. RespireRx’s programs remain subject to clinical development and regulatory review, and the company’s publicly available materials provide limited information about current operations, geographic activities, and leadership.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 300 shs
• Average Volume: 928,930 shs
• Market Capitalization: $130 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:RSPID
• CIK: N/A
• Web: www.respirerx.com
• Phone: 201 444 4947
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 72,271,000
• Free Float: N/A
• Market Cap: $130 thousand
• Optionable: Not Optionable
• Beta: 0.15